Information technology has made significant contributions to
our world, especially in the medical industry. Medical technology has evolved
from introducing doctors to new equipment to use inside private practices and
hospitals to connecting patients and doctors thousands of miles away through
telecommunications. Even more, medical scientists and physicians are constantly
conducting research and testing new procedures to help prevent, diagnose, and
cure diseases as well as developing new drugs and medicines that can lessen
symptoms or treat ailments.
For example, BioSig Technologies, a Connecticut-based medicaltechnology company working on advanced biomedical signal processing technology,
has been able to improve fidelity of acquired cardiac signals that may
potentially increase the diagnostic value of these signals, thereby possibly
improving accuracy and efficiency of the EP studies and related procedures. BioSig’s
commitment toward offering higher quality of patient care by introducing
innovative technological solutions to medicine, has yield some impressive
growth in the medical device sector.
With more and more hospitals and practices using medical
technology like mobile devices on the job, physicians can now have access to
any type of information they need – from drug information, research and
studies, patient history or records, and more – within mere seconds.
Last November, BioSig had signed a research program deal
with Mayo Clinic which consisted of several two-to-three-year projects,
focusing on the development of additional advanced features of their first
product, the PURE EP system, within the field of electrophysiology. This novel
cardiac signal acquisition and display system is engineered to assist
electrophysiologists in clinical decision-making during electrophysiology procedures
in patients with abnormal heart rates and rhythms.
BioSig’s ultimate goal is to
deliver technology to improve upon catheter ablation treatments for the
prevalent and potentially deadly arrhythmias, Atrial Fibrillation and
Ventricular Tachycardia.
Led by their CEO Ken Londoner, a proven management team and
a veteran Board of Directors, BioSig Technologies is preparing to commercialize
its PURE EPTM System. The technology has
been developed to address an unmet need in a large and growing market. BioSig
is currently focusing on the development of a proprietary biomedical signal
processing platform, engineered to meet excess demand for technology in the
electrophysiology (EP) marketplace.
